-
2022-501744-15-00
5
2023-01-23
Obesity, Overweight
-
2024-514147-28-00
5
2022-12-02
Primary immune thrombocytopenia
-
2023-503403-28-00
4
2022-11-25
treatment naïve patients with HR+/HER2-negative high-risk early breast
-
2023-509859-13-00
5
2022-11-09
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-511412-25-00
4
2022-11-07
First line treatment for extensive-stage small cell lung cancer small
-
2023-505866-27-00
5
2022-10-28
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-517008-12-00
5
2022-10-14
Newly-diagnosed multiple myeloma (NDMM)
-
2024-518870-15-00
4
2022-10-03
Multiple Myeloma
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2024-511268-10-00
4
2022-05-25
Unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cel
-
2023-510097-14-00
5
2022-04-15
Patients with MMR deficient relapse or advanced / metastatic endometri
-
2023-506771-10-00
5
2022-03-11
Breast Neoplasm, Neoplasm Metastasis
-
2024-515092-36-00
5
2022-02-14
Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-508248-23-00
5
2021-11-26
Non-alcoholic steatohepatitis (NASH)
-
2024-510735-21-00
5
2021-11-26
Atherosclerotic cardiovascular disease (ASCVD)
-
2024-517006-28-00
9
2021-11-23
Multiple myeloma
-
2024-513866-20-00
4
2021-11-18
Non-small cell lung cancer with brain metastasis
-
2023-503441-55-00
4
2021-10-14
Relapsed/Refractory Multiple Myeloma
-
2024-516039-28-00
6
2021-09-28
Spontaneous Coronary Artery Dissection.
-
2024-510750-28-00
4
2021-06-18
Tumours of the urothelial tract requiring surgery (T1 high grade-T4a o
-
2023-504684-16-00
5
2021-06-05
follicular lymphoma (FL) and marginal zone lymphoma (MZL)
-
2023-507961-24-00
5
2021-04-19
High-Risk HER2-Positive Breast Cancer
-
2023-508829-28-00
4
2021-03-15
Pre- and post-menopausal women or men with advanced (loco regionally r